Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: phbolton who wrote (593)	5/4/1998 10:07:00 PM
From: David Winkler	Read Replies (1) \| Respond to of 2135

one of the reasons that this approach is so likely to succeed is that the "drug" is not a drug. It is a naturally occurring molecule that is produced by normal cells to regulate the growth of new blood vessels. Normally these are active only during fetal development and wound healing. The tumor stimulates the vessels to grow and feed them, thus allowing it to grow. This molecule does not have many severe side effects because it is a normally occurring molecule. It attacks a very basic need of the tumor, the need for nutrients. This is the reason that the professionals are so optimistic about it. No matter what the outcome this work is a huge breakthrough in understanding basic biology. That won't add to the bottom line, but who knows where it might lead.